Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS), Canadian Organization of Rare Disorders (CORD), and The Global Genes Project in observance of the annual Rare Disease Day.
Chief Operating Officer Jeff Hackman commented, "Novelion is proud to join our community to raise awareness of rare diseases. Mindful of the challenges these patients, their families and caregivers face, we are motivated by a passion to support advocacy and aspire to develop innovative treatments for patients with rare diseases."
In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was established by EURORDIS and was first observed in Europe in 2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S. For more information about Rare Disease Day, visit www.rarediseaseday.org.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT and JUXTAPID, and is also developing zuretinol acetate for the potential treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com (mailto:amanda.murphy@novelion.com)
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novelion Therapeutics Inc. via Globenewswire
